The direct medical costs of late presentation (< 350 / mm 3) of HIV infection over a 15-year period

AIDS Research and Treatment

Volumn 2012, Issue , 2012, Pages

  Krentz, Hartmut B ^a,b   Gill, M John ^a,b  

^a Sheldon M Chumir Health Centre   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861029771     PISSN: 20901240     EISSN: 20901259     Source Type: Journal    
DOI: 10.1155/2012/757135     Document Type: Article

References (54)

1. Tolley K., Gyldmark M., The treatment and care costs of people with HIV infection or AIDS: development of a standardised cost framework for Europe. Health Policy 1993 24 1 55 70 2-s2.0-0027273558 10.1016/0168-8510(93)90088-7 (Pubitemid 23154848)
2. Bloom D. E., Carliner G., The economic impact of AIDS in the United States. Science 1988 239 4840 604 610 2-s2.0-0023872618 (Pubitemid 18066221)
3. Hellinger F. J., Forecasts of the costs of medical care for persons with HIV: 1992-1995. Inquiry 1992 29 3 356 365 2-s2.0-0026640665
4. Albert T., William G., The economic burden of HIV/AIDS in Canada: summary of the findings and policy implications. CPRN Study 1997 H[02]
5. Anis A. H., Hogg R. S., Yip B., Wang X. H., Montaner J. S. G., O'Shauglinessy M. V., Schechter M. T., Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men and women. Pharmacoeconomics 1998 13 3 327 336 2-s2.0-0031916173 10.2165/00019053- 199813030-00007 (Pubitemid 28123372)
6. Freedberg K. A., Scharfstein J. A., Seage G. R., Losina E., Weinstein M. C., Craven D. E., Paltiel A. D., The cost-effectiveness of preventing AIDS-related opportunistic infections. Journal of the American Medical Association 1998 279 2 130 135 2-s2.0-0032515391 10.1001/jama.279.2.130 (Pubitemid 28068303)
7. Beck E. J., Mandalia S., Gaudreault M., Brewer C., Zowall H., Gilmore N., Klein M. B., Lalonde R., Piché A., Hankins C. A., The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS 2004 18 18 2411 2418 2-s2.0-19944427643 (Pubitemid 40065908)
8. Hanvelt R. A., Ruedy N. S., Hogg R. S., Strathdee S., Montaner J. S. G., O'Shaughnessy M. V. O., Schechter M. T., Indirect costs of HIV/AIDS mortality in Canada. AIDS 1994 8 10 F7 F11 2-s2.0-0028040847 (Pubitemid 24296792)
9. Mullins C. D., Whitelaw G., Cooke J. L., Beck E. J., Indirect cost of HIV infection in England. Clinical Therapeutics 2000 22 11 1333 1345 2-s2.0-0033646365 10.1016/S0149-2918(00)83030-1
10. Farquhar I., Sorkin A., Summers K., Weir E., Estimating economic cost of HIV/AIDS-related diseases. Investing in Health: The Social and Economic Benefits of Health Care Innovation 2001 Emerald Group Publishing Limited 143 173 (Pubitemid 33804912)
11. Beck E. J., Miners A. H., Tolley K., The cost of HIV treatment and care: a global review. Pharmacoeconomics 2001 19 1 13 39 2-s2.0-0035150913 (Pubitemid 32113370)
12. Hellinger F. J., The lifetime cost of treating a person with HIV. Journal of the American Medical Association 1993 270 4 474 478 2-s2.0-0027235750 10.1001/jama.270.4.474 (Pubitemid 23223485)
13. Gebo K. A., Chaisson R. E., Folkemer J. G., Bartlett J. G., Moore R. D., Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999 13 8 963 969 2-s2.0-0032968155 10.1097/00002030-199905280-00013 (Pubitemid 29240192)
14. Keiser P., Nassar N., Kvanli M. B., Turner D., Smith J. W., Skiest D., Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. Journal of Acquired Immune Deficiency Syndromes 2001 27 1 14 19 2-s2.0-0035329587 (Pubitemid 32587237)
15. Bozzette S. A., Joyce G., McCaffrey D. F., Leibowitz A. A., Morton S. C., Berry S. H., Rastegar A., Timberlake D., Shapiro M. F., Goldman D. P., Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. New England Journal of Medicine 2001 344 11 817 823 2-s2.0-0035869519 10.1056/NEJM200103153441107 (Pubitemid 32222161)
16. Krentz H. B., Auld M. C., Gill M. J., The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ 2003 169 2 106 110 2-s2.0-0041352971 (Pubitemid 36963222)
17. Krentz H. B., Auld M. C., Gill M. J., The high cost of medical care for patients who present late (CD4200 cells/ μ L) with HIV infection. HIV Medicine 2004 5 2 93 98 2-s2.0-1642565257 10.1111/j.1468-1293.2004.00193.x (Pubitemid 38404662)
18. Palella F. J. Jr., Delaney K. M., Moorman A. C., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. The New England Journal of Medicine 1998 338 853 860 (Pubitemid 28135961)
19. Egger M., egger@ispm.unibe.ch May M., Chêne G., Phillips A. N., Ledergerber B., Dabis F., Costagliola D., D'Arminio Monforte A., De Wolf F., Reiss P., Lundgren J. D., Justice A. C., Staszewski S., Leport C., Hogg R. S., Sabin C. A., Gill M. J., Salzberger B., Sterne J. A.C., Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002 360 9327 119 129 10.1016/S0140-6736(02)09411-4 (Pubitemid 34786200)
20. Montaner J. S. G., Hogg R. S., Weber A. E., Anis A. H., O'Shaughnessy M. V., Schecter M. T., The costs of triple-drug anti-HIV therapy or adults in the Americas. Journal of the American Medical Association 1998 279 16 1263 1264 2-s2.0-0032557168 10.1001/jama.279.16.1263
21. Gebo K. A., Chaisson R. E., Folkemer J. G., Bartlett J. G., Moore R. D., Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999 13 8 963 969 2-s2.0-0032968155 10.1097/00002030-199905280-00013 (Pubitemid 29240192)
22. Moore R. D., Cost effectiveness of combination HIV therapy: 3 years later. Pharmacoeconomics 2000 17 4 325 330 2-s2.0-0034107574 (Pubitemid 30236167)
23. Lavalle C., Aguilar J. C. D., Pena F., Estrada-Aguilar J. L., Avina-Zubieta J. A., Madrazo M., Reduction in hospitalization costs, morbidity, disability, and mortality in patients with AIDS treated with protease inhibitors. Archives of Medical Research 2000 31 5 515 519 2-s2.0-0034633091 10.1016/S0188-4409(00)00097-7 (Pubitemid 32114184)
24. Freedberg K. A., Losina E., Weinstein M. C., Paltiel A. D., Cohen C. J., Seage G. R., Craven D. E., Zhang H., Kimmel A. D., Goldie S. J., The cost effectiveness of combination antiretroviral therapy for HIV disease. New England Journal of Medicine 2001 344 11 824 831 2-s2.0-0035869435 10.1056/ NEJM200103153441108 (Pubitemid 32222162)
25. Miners A., Sabin C., Trueman P., Youle M., Mocroft A., Johnson M., Beck E., Assessing the cost-effectiveness of highly active antiretroviral therapy for adults with HIV in England. HIV Medicine 2001 2 1 52 58 2-s2.0-0035204908 10.1046/j.1468-1293.2001.00048.x (Pubitemid 33114503)
26. Levy A. R., James D., Johnston K. M., Hogg R. S., Harrigan P. R., Harrigan B. P., Sobolev B., Montaner J. S., The direct costs of HIV/AIDS care. Lancet Infectious Diseases 2006 6 3 171 177 2-s2.0-33144480683 10.1016/S1473-3099(06)70413-3 (Pubitemid 43267642)
27. Girardi E., Arici C., Ferrara M., Ripamonti D., Aloisi M. S., Alessandrini A., Scalzini A., D'Arminio Monforte A., Serraino D., Ippolito G., Estimating duration of HIV infection with CD4 cell count and HIV-1 RNA at presentation. AIDS 2001 15 16 2201 2203 2-s2.0-0035834463 10.1097/00002030- 200111090-00021 (Pubitemid 33101833)
28. Sax P. E., Stage of HIV Disease at Time of Diagnosis. AIDS Clinical Care 2003 1 4
29. Palella F. J., Deloria-Knoll M., Chmiel J. S., Moorman A. C., Wood K. C., Greenberg A. E., Holmberg S. D., Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Annals of Internal Medicine 2003 138 8 620 I28 2-s2.0-0038662719
30. Chen R. Y., Accortt N. A., Westfall A. O., Mugavero M. J., Raper J. L., Cloud G. A., Stone B. K., Carter J., Call S., Pisu M., Allison J., Saag M. S., Distribution of health care expenditures for HIV-infected patients. Clinical Infectious Diseases 2006 42 7 1003 1010 2-s2.0-33645058159 10.1086/500453
31. Krentz H. B., Gill J., Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 μ l. AIDS 2010 24 17 2750 2753 2-s2.0-78349312875 10.1097/QAD.0b013e32833f9e1d
32. Fleishman J. A., Yehia B. R., Moore R. D., Gebo K. A., The economic burden of late entry into medical care for patients with HIV infection. Medical Care 2010 48 12 1071 1079 2-s2.0-78650174026 10.1097/MLR.0b013e3181f81c4a
33. Ledergerber B., Egger M., Opravil M., Telenti A., Battegay M., Vernazza P., Sudre P., Flepp M., Furrer H., Francioli P., Weber R., Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999 353 9156 863 868 2-s2.0-0033550965 10.1016/S0140-6736(99)01122-8 (Pubitemid 29126872)
34. Egger M., May M., Chêne G., Phillips A. N., Ledergerber B., Dabis F., Costagliola D., D'Arminio Monforte A., De Wolf F., Reiss P., Lundgren J. D., Justice A. C., Staszewski S., Leport C., Hogg R. S., Sabin C. A., Gill M. J., Salzberger B., Sterne J. A. C., Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002 360 9327 119 129 2-s2.0-0037072066 10.1016/S0140-6736(02) 09411-4 (Pubitemid 34786200)
35. Castilla J., Sobrino P., De La Fuente L., Noguer I., Guerra L., Parras F., Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 2002 16 14 1945 1951 2-s2.0-0037183869 10.1097/00002030-200209270-00012
36. Sabin C. A., Smith C. J., Gumley H., Murphy G., Lampe F. C., Phillips A. N., Prinz B., Youle M., Johnson M. A., Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004 18 16 2145 2151 2-s2.0-7744227969 10.1097/00002030-200411050- 00006 (Pubitemid 39463679)
37. Chadborn T. R., Delpech V. C., Sabin C. A., Sinka K., Evans B. G., The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006 20 18 2371 2379 2-s2.0-33751209461 10.1097/QAD.0b013e32801138f7 (Pubitemid 44789540)
38. Girardi E., Sabin C. A., Monforte A. D., Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. Journal of Acquired Immune Deficiency Syndromes 2007 46 1 S3 S8 2-s2.0-34548172741 10.1097/01.qai.0000286597.57066.2b (Pubitemid 47312320)
39. May M., m.t.may@bristol.ac.uk Sterne J. A.C., Sabin C., Costagliola D., Justice A. C., Thiébaut R., Gill J., Phillips A., Reiss P., Hogg R., Ledergerber B., Monforte A. D'A., Schmeisser N., Staszewski S., Egger M., Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007 21 9 1185 1197 10.1097/QAD.0b013e328133f285 (Pubitemid 46763289)
40. Adler A., Mounier-Jack S., Coker R. J., Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care 2009 21 3 284 293 2-s2.0-70449674893 10.1080/09540120802183537
41. Branson B. M., Handsfield H. H., Lampe M. A., Janssen R. S., Taylor A. W., Lyss S. B., Clark J. E., Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. Morbidity and Mortality Weekly Report 2006 55 -14 1 CE1 2-s2.0-33748857193
42. Walensky R. P., Weinstein M. C., Kimmel A. D., Seage G. R., Losina E., Sax P. E., Zhang H., Smith H. E., Freedberg K. A., Paltiel A. D., Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. American Journal of Medicine 2005 118 3 292 300 2-s2.0-20044376074 10.1016/j.amjmed.2004.07.055 (Pubitemid 40312641)
43. Paltiel A. D., Walensky R. P., Schackman B. R., Seage G. R., Mercincavage L. M., Weinstein M. C., Freedberg K. A., Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Annals of Internal Medicine 2006 145 11 797 806 2-s2.0-34147203610 (Pubitemid 351650333)
44. Montaner J. S., Hogg R., Wood E., Kerr T., Tyndall M., Levy A. R., Harrigan P. R., The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006 368 9534 531 536 2-s2.0-33746512140 10.1016/S0140-6736(06)69162-9 (Pubitemid 44142776)
45. Granich R. M., Gilks C. F., Dye C., De Cock K. M., Williams B. G., Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. The Lancet 2009 373 9657 48 57 2-s2.0-58149097694 10.1016/S0140-6736(08)61697-9
46. Attia S., Egger M., Müller M., Zwahlen M., Low N., Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009 23 11 1397 1404 2-s2.0-68449085124 10.1097/QAD.0b013e32832b7dca
47. Wagner B. G., Kahn J. S., Blower S., Should we try to eliminate HIV epidemics by using a Test and Treat strategy? AIDS 2010 24 5 775 776 2-s2.0-77949368491 10.1097/QAD.0b013e3283366782
48. Lange J. M. A., 'Test and Treat': is it enough? Clinical Infectious Diseases 2011 52 6 801 802
49. Gardner E. M., edward.m.gardner@dhha.org McLees M. P., Steiner J. F., Del Rio C., Burman W. J., The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical Infectious Diseases 2011 52 6 793 800 10.1093/cid/ciq243
50. Krentz H. B., Gill M. J., Impact of expanded HIV screening. Annals of Internal Medicine 2007 147 2 146 2-s2.0-34547117864
51. Rosen S., Long L., How much does it cost to provide antiretroviral therapy for HIV/AIDS in Africa? Health and Development Discussion Paper 2006 9 Center for International Health and Development. Boston University
52. Callaghan M., Ford N., Schneider H., A systematic review of task- shifting for HIV treatment and care in Africa. Human Resources for Health 2010 8, article no. 8 2-s2.0-77953333225 10.1186/1478-4491-8-8
53. Nachega J. B., Leisegang R., Bishai D., Nguyen H., Hislop M., Cleary S., Regensberg L., Maartens G., Association of antiretroviral therapy adherence and health care costs. Annals of Internal Medicine 2010 152 1 18 25 2-s2.0-74849120025
54. Martinson N., Mohapi L., Bakos D., Gray G. E., McIntyre J. A., Holmes C. B., Costs of providing care for HIV-infected adults in an urban HIV clinic in soweto, South Africa. Journal of Acquired Immune Deficiency Syndromes 2009 50 3 327 330 2-s2.0-63149185454 10.1097/QAI.0b013e3181958546